A Population Pharmacokinetic–Pharmacodynamic Analysis of Repeated Measures Time-to-Event Pharmacodynamic Responses: The Antiemetic Effect of Ondansetron
暂无分享,去创建一个
Lewis B. Sheiner | Stuart L. Beal | L. Sheiner | E. Cox | Christine Veyrat-Follet | C. Veyrat‐Follet | Eugène H. Cox | Eliane Fuseau | Saraswati Kenkare | S. Beal | E. Fuseau | S. Kenkare | C. Veyrat-Follet
[1] C. Felgate,et al. Determination of ondansetron in plasma and its pharmacokinetics in the young and elderly. , 1991, Journal of pharmaceutical sciences.
[2] David B. Dunson,et al. Bayesian Data Analysis , 2010 .
[3] N H Holford,et al. Simulation of clinical trials. , 2000, Annual review of pharmacology and toxicology.
[4] Adrian Dunne,et al. Analysis of Nonrandomly Censored Ordered Categorical Longitudinal Data from Analgesic Trials , 1997 .
[5] M. Danhof,et al. Pharmacokinetic-pharmacodynamic modeling of CNS drug effects: an overview. , 1988, Pharmacology & therapeutics.
[6] D. Harrington,et al. Counting Processes and Survival Analysis , 1991 .
[7] L B Sheiner,et al. A new approach to the analysis of analgesic drug trials, illustrated with bromfenac data , 1994, Clinical pharmacology and therapeutics.
[8] John D. Kalbfleisch,et al. The Statistical Analysis of Failure Data , 1986, IEEE Transactions on Reliability.
[9] Lewis B. Sheiner,et al. Building population pharmacokineticpharmacodynamic models. I. Models for covariate effects , 1992, Journal of Pharmacokinetics and Biopharmaceutics.
[10] C. Lawlor,et al. Ipecacuanha‐induced emesis: A human model for testing antiemetic drug activity , 1993, Clinical pharmacology and therapeutics.
[11] D. Collet. Modelling Survival Data in Medical Research , 2004 .
[12] D. Stanski,et al. A three-step approach combining bayesian regression and NONMEM population analysis: Application to midazolam , 1991, Journal of Pharmacokinetics and Biopharmaceutics.
[13] S. Wring,et al. A sensitive radioimmunoassay, combined with solid-phase extraction, for the sub-nanogram per ml determination of ondansetron in human plasma. , 1994, Journal of pharmaceutical and biomedical analysis.
[14] W. Colburn,et al. Efficacy Measures: Surrogates or Clinical Outcomes? , 1996, Journal of clinical pharmacology.
[15] Xiao-Li Meng,et al. POSTERIOR PREDICTIVE ASSESSMENT OF MODEL FITNESS VIA REALIZED DISCREPANCIES , 1996 .
[16] J. Kalbfleisch,et al. The Statistical Analysis of Failure Time Data , 1980 .
[17] D R Stanski,et al. Plasma Concentrations of Alfentanil Required to Supplement Nitrous Oxide Anesthesia for General Surgery , 1986, Anesthesiology.
[18] D. Cox,et al. A General Definition of Residuals , 1968 .
[19] R. Maller,et al. Survival Analysis with Long-Term Survivors , 1996 .
[20] D J Sargent,et al. A general framework for random effects survival analysis in the Cox proportional hazards setting. , 1998, Biometrics.
[21] Sheldon M. Ross,et al. Stochastic Processes , 2018, Gauge Integral Structures for Stochastic Calculus and Quantum Electrodynamics.
[22] P. Grambsch,et al. Martingale-based residuals for survival models , 1990 .
[23] D R Stanski,et al. Population pharmacodynamic model for ketorolac analgesia , 1996, Clinical pharmacology and therapeutics.